Distributed facility for fragment based drug discovery

  • Scanlon, Martin (Primary Chief Investigator (PCI))
  • Dixon, Nicholas (Chief Investigator (CI))
  • Gooley, Paul R. (Chief Investigator (CI))
  • Hughes, Richard Anthony (Chief Investigator (CI))
  • Kwan, Ann (Chief Investigator (CI))
  • Lewis, Peter (Chief Investigator (CI))
  • Mackay, Joel (Chief Investigator (CI))
  • Matthews, Jacqueline (Chief Investigator (CI))
  • Norton, Raymond (Chief Investigator (CI))
  • Oakley, Aaron J. (Chief Investigator (CI))
  • Scammells, Peter (Chief Investigator (CI))

Project: Research

Project Details

Project Description

There is an unmet need for the capacity to generate small molecules that modulate therapeutically and
biologically important protein targets.
Fragment-based drug design (FBDD) provides a rational approach to generate such biologically active
The Distributed FBDD Facility will provide a mechanism for researchers throughout Australia to access the
necessary infrastructure to undertake FBDD projects against a range of biologically important targets. The facility
will enable access to high-throughput NMR spectroscopy and surface plasmon resonance, it will generate the
capacity for automation in chemical synthesis and sample preparation to expedite the development of novel
bioactive molecules.
Effective start/end date1/01/1627/09/16


  • Australian Research Council (ARC): A$380,000.00
  • Monash University: A$115,468.00
  • Monash University: A$57,734.00
  • University of Sydney: A$173,203.00
  • University of Wollongong: A$12,990.00
  • University of Newcastle: A$25,980.00
  • University of Melbourne: A$17,320.00